Amarin Corp PLC News - AMRN

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Form 8-K - Current report

Amarin Board of Directors Announces CEO Transition

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to...

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce...

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN...

Amarin Reports First Quarter 2024 Business Update and Financial Results

-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe...

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

DUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

Amarin Announces Results of Annual General Meeting of Shareholders

DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

DUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups Canada...

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a...

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

DMC8 13 seconds ago

Please LIKE all the comments in REDDIT post!!
https://stocktwits.com/SanDiegoLiving/message/578618644

👍️0

Downtownguy 2 minutes ago

RMB I made that post before the CVS news came out

👍️0

rosemountbomber 29 minutes ago

All good points made by RoaringKitty save for the one sentence about US revenues stabilizing. They are about to take a 25% haircut starting July 1.

👍️ 1

ziploc_1 1 hour ago

North...I did see the article on taking Semaglutudes being associated with NAION...

"The precise pathogenesis of NAION remains unclear, but it has been hypothesized that transient HYPOPERFUSION of the short posterior ciliary arteries causes acute ischemia to the optic nerve head (ONH), resulting in axonal swelling. This swelling compromises the axoplasmic flow, which subsequently increases the axonal swelling, contributing to the compression of ONH microcirculation, exacerbating the ischemia. This vicious cycle creates a compartment syndrome, eventually leading to infarction and apoptosis of the retinal ganglion cells "

I believe that studies that will now need be done by Sematutide companies to show whether there is any lessening in the risk of developing NAION...

1. for diabetic patients, who are NOT taking Samaglutide meds as opposed to those, who are.
2. for diabetic patients, who taking Semaglutide meds, but also taking Vascepa
3. for diabetic patients , who are taking NEITHER Semaglutides nor Vascepa.

👍️0

DMC8 1 hour ago

Fellow genuine longs, please like this post and make it VIRAL on REDDIT!
https://www.reddit.com/r/roaringkitty/s/l2JcJI9KZK

👍️ 4

north40000 2 hours ago

Question: will this same mechanism affect BRAVE Vascepa trial results for Alzheimer’s, dementia, also in a positive sense?

Ziploc, did you see NVO price action premarket in light of Mass Eye data on potential blindness from Ozempic, Wegovy interrupting blood flow to optic nerve? Something else for FDA to investigate with respect to those 2 weight loss drugs?

👍️ 1

DMC8 2 hours ago

This is re-posted by Dr Bhatt on X as well.

👍️ 1

ziploc_1 3 hours ago

DMC...Thank you for posting this interesting article...For those us, who are less familiar with the scientific terminology in the article, I took away the following message...

1. Loss of endothelial function is associated with inflammation which, in turn, is associated with a DECREASE in the availability of nitrous oxide
2. EPA INCREASES the availablity of nitrous oxide...and is the mechanism, whereby systemic inflammation is DECREASED...along with endothelial function being INCREASED....This factor consequently results in healthier arteries throughout the body..(including the mechanism, which explains the reduction in CVD for patients using EPA.
.

👍️ 3

DMC8 4 hours ago

Researchers report new insights into the mechanism of action of eicosapentaenoic acid (EPA), an omega-3 fatty derived from fish, against inflammation and atherosclerosis. The findings in cell studies support EPA therapy for patients at high risk for #CVD. https://t.co/SK3Je71wWm pic.twitter.com/UD2SU9EzKz— NIH NHLBI (@nih_nhlbi) July 3, 2024

👍️0

Number sleven 7 hours ago

https://www.pacermonitor.com/public/case/40022951/DR_REDDYS_LABORATORIES_INC_v_AMARIN_PHARMA,_INC_et_al
Sleven,

👍️0

DMC8 9 hours ago

A very skillful fake bull indeed.

👍️ 1

scxj 10 hours ago

Bob Good aka Bipolar Bob. Or should I say Bad news Bob. Total ignore.

👍️ 3

DMC8 10 hours ago

Bob good is fake bull

👍️ 1

Nukemtiltheyglow 16 hours ago

Glad to see Zuckerberg supporting Coors. Is that a Coors Tall Boy he's drinking? :D)
Quite the acrobat.

👍️0

rosemountbomber 16 hours ago

Sorry if already posted. Piece on the Appeals Court decision:

https://www.polsinelli.com/publications/federal-circuit-clarifies-rules-for-skinny-labelling-for-generics-and-biosimilar-companies.

Also, read a post on ST, that had an interesting question. Obviously, far off in the distance and assuming Amarin went on to win a judgement against Hikma:

"
BobGood
5:28 AM
$AMRN
I see lots of discussions in iHub, about if $AMRN wins the legal case against Hikma, Hikma will be forced to stop selling it’s IPE generics to CVD patients in future.
If this happens, all longs will be very happy for ever as this rule will be applied to other generics as well…
That’s okay and I can understand up to this point !!
But, importantly, how this will be implemented on the ground and who will be accountable to ensure this is achieved?
How & who will be monitoring and guiding the CVD scripts Vs VHTG scripts at the tens of thousands of dispensing pharmacies levels across the country??
What will be the actual mechanism to achieve this?? Just curious.. "

👍️0

CaptBeer 16 hours ago

speaking of Endothelial Dysfunction: Check out these new findings from AJAH: https://t.co/dawaVpvIWY
Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation— Mike Everts (@GeoWizz_) July 4, 2024

👍️ 2

ramfan60 20 hours ago

These weight loss drugs drive me crazy...... for the same reason people need to take V...... they don't bother to eat properly..... put physical activity aside, people eat like crap. Nutrition "experts" push a balanced diet heavy on carbs...... hence we end up with a fat population with type 2 diabetes and metabolic diseases. It's so damn simple...... carbs convert to sugar, people eat too many and they don't burn it all so it turns to fat. Too much sugar causes insulin resistance. Replace the carbs with eating fat as your energy source and you become fat adapted. You'll lose the weight and become metabolically healthy....... if any of my fellow posters have an issue with trying to lose weight and inches around your waist and you've tried all the fad diets and drugs, cut out the carbs and replace them with high fat meats of all kinds (not processed meats).....it's pretty simple really.

👍️ 2

Whalatane 21 hours ago

Since its the 4th Mark Zuckerberg celebrating Fourth of July.

pic.twitter.com/YCn6eNiELy— Pop Tingz (@ThePopTingz) July 4, 2024

Kiwi

👍️0

Number sleven 21 hours ago

Sts,
https://www.courtlistener.com/docket/18701895/amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/
This is the filing history of the suit. You will notice that an insurance provider, Health Net, was also included in the suit. The allegation against Health Net was not dismissed. Eventually it was settled.
Sleven,

👍️0

rosemountbomber 22 hours ago

I have to defer to attorneys or those who know much more than me about infringement and damages. Right now for me, I see the current situation as one where Amarin has to try to hang onto US sales as much as possible for long enough to get EU revenues going - if and when that ever happens (I'm from Missouri with this stock so have to see it). Then you have the lottery tickets as I would call them.... the lawsuits and new study results for other indications. And of course, I am still under the impression that Denner's goal is to sell the company. Question is, will it be if and after the company starts producing significant earnings, or will he abandon waiting and dump it at a bargain basement valuation. Patiently waiting, but since I have to start disbursements from the retirement accounts next year (turning 73 next year), I am hoping something happens not too long after that.

👍️0

sts66 22 hours ago

Thanks for the info sleven - this is more complicated than I thought! Guess I'll just wait to see how things play out over time, and will have to start checking this board again, because from what's happened so far I won't hear about progress in the trial anywhere else. IR not releasing a PR about the CAFC ruling is just bizarre to me - they need every bit of positive news they can get, so why sit on the news when it occurs?

👍️0

sts66 22 hours ago

When I wrote that post I was thinking about what you just wrote - IIRC, AMRN's patent protection for R-IT expires in 2029, so if this case takes years to get through the court system it will pretty much be too late to help AMRN recover the entire R-IT market and return to growing sales. IANAL, so I don't know whether if AMRN eventually prevails whether they can try to recover damages or treble damages since this case is about willful infringement - and I think (don't know) that any damages would just come from Hickma - they'd have to sue every other generic maker for the same infringement to recover damages.

Side question about will AMRN exist in it's current form 3-5 yrs from now - if they get delisted, and I don't see any way it's not going to happen, then what? Most companies die when they go to the OTC markets - worse, SEC requirements for OTC stocks are very small - they don't have to issue 8-K's or financial reports (although they can if they want to), so there's no way to know what's going on inside the C-suite unless IR issues PRs about certain events. I won't get into the topic of "how does AMRN avoid getting delisted?" - I'm sure it's been widely discussed here already and I'm not going to ask anyone to rehash things - I was the one who made the decision to stop reading this board with any kind of regularity so it's my fault I don't know what's been going on. Sure wish IHUB freeloaders could search boards for keywords

👍️0

north40000 24 hours ago

Had not seen that interview, Jasbg. I appreciate the link.

👍️ 1

Jasbg 24 hours ago

North, Talking Ozempic - did you see the interview below ?

https://tuckercarlson.com/the-case-against-ozempic

👍️0

Whalatane 1 day ago

Re your comment What is the point of all these positive studies if nobody is willing and
able to sell the drug?

Well the point is " weight of the evidence ". The more evidence you can collect to demonstrate benefit , the more chance you have of persuading Health systems in the EU to provide generous reimbursement. enabling more sales of the drug.

Of course theres different levels of evidence ...large double blinded randomized clinical trial , smaller versions in sub groups , Real World Evidence and then studies like this one that Capt linked.

Have 4th y'all
Kiwi

👍️0

north40000 1 day ago

Post # 252470 by jbog starts the discussion, other # is incorrect.

👍️0

north40000 1 day ago

Anyone here being prescribed NVO’s weight loss drugs Ozempic or Wegovy should look at discussion of links to a Mass Eye JAMA paper published yesterday, beginning with a jbog post ‘271 on the Biotech Value message board. Risk of blindness from an interruption of blood flow to an optic nerve is the issue.

👍️0

Number sleven 2 days ago

Sts, Hikma made an advertising mistake. They claimed that their generic was approved for our indication without actually making a CVD label claim. That in combination with portions of the generic label opens them up to litigation. The other generic companies didn't make the same mistake. Rulings that happen as this suit progresses might open up legal action against the other generic companies. Negotiating exclusive agreements with insurance companies or PBM's is probably considered an overt act proving inducement.
Sleven,

👍️0

rosemountbomber 2 days ago

STS, I think the reason that it is hard for too many people to get too worked up about this is that it will be a long, long, and winding road for it to run to conclusion if Amarin were to prevail. Years, maybe close to a decade with appeals and such. Some think Amarin won't exist in the form it is now by the time this is settled. Hopefully that is a very pessimistic outlook and something transpires to bring this to the forefront in a much quicker timeframe.

👍️0

sts66 2 days ago

Thanks for the info - generic labels being the same is big - if Hikma loses they all have to stop selling GV for CVD use, which is 99% of their sales. I assume the 1st case was to accuse Hikma of potential patent/label violations, and the 2nd one is actual infringement because AMRN had a few years of GV sales to look at to prove infringement? Sort of surprised AMRN didn't issue a PR about the 2nd suit - I don't recall getting an email alert from IR about this, but if it was in an email that just said "new 8-K filed" I could have missed it - I don't read half of those because they're essentially meaningless. But I would think someone would have written about this for Seeking Alpha, or an author who follows AMRN would have said something about it in comments for a different AMRN article. If I don't get an email alert directly from a company or from SA it's like it never happened, I won't know about it. That's one of the big reasons I just left Schwab (damn I miss TDA!) for Fidelity - Schwab won't send you email alerts when one of your stocks go ex-div, or alert you the day before payable date so I didn't know to check the website to download transactions and update Excel and my stock software cost basis. This made the transition to Fido way, way more difficult than it should have been (still ain't over) - I reinvest all divs, and 3 of my stocks/funds paid divs (new shrs to me) after I started the transfer - I would have waited another week to do it had I known divs were coming. You can't transfer fractional shrs for some reason, so I had to adjust the basis for those 3 twice, once for the original stock transfer and then for the DRIP shrs.

After re-reading what I wrote I'm even more flabbergasted that nobody on SA has written about this lawsuit - am I wrong in thinking this is a big deal for AMRN and the generics?

👍️0

Jasbg 2 days ago

liamlinden, Up $128k - did you sell then ? 🙂

👍️0

Monk4444 2 days ago

BAM
I’ll buy all 10 of your shares for
$2.70 now

👍️ 1

couldbebetter 2 days ago

Strange that with so much proof that pure EPA is beneficial
for patients with CVD yet Vascepa will remain unknown in the
US. However, I hope Europe will turn out different. With exclusivity
running to 2039 one would think there has to be a BP out there who
could turn Vazkepa into a blockbuster product. With Dr. Bhatt on the
BOD of BMY you have to wonder if he ever puts forward a BO idea
so that at least Vazkepa could have a shot with BP backing in Europe.
What is the point of all these positive studies if nobody is willing and
able to sell the drug?

👍️ 1

CaptBeer 2 days ago

Yep, It's the EPA Stupid!
Now out in @JAHA_AHA, more data supporting the cardiovascular benefits of EPA. #cardiology #cardiotwitter #cardioX https://t.co/YqnbTmCeMm— Dr. Deepak L. Bhatt (@DLBHATTMD) July 3, 2024

liamlinden 2 days ago

Rose The CEO Kelly martin told me before the AGM that he found out about the pml when he got off the plane in new york his mobile was beeping ring tones for 15 minutes .Never know a CEO personally to speak 2 it spells disaster.Elan and Amarin had similar journeys but in the end I came out ok with Elan.This day 5 years ago I went from Detroit to Grand Rapids for 4th of July and when we got to Grand Rapids I was up $128k when i got out of the car .

👍️0

Number sleven 2 days ago

Captain, I doubt it. China made Mochida run an independent study in order to apply for the SHTG indication.
Sleven,

👍️ 1

ralphey 2 days ago

Sixty Eight pennies and yet hope springs eternal for the desperate housewives of Investors HUb . That CAD AMRN wont even pump you anymore !

Liam, thanks for that backstory. My biggest fear is Sarissa doing something sinister to come out ahead on this. We can only hope that Denner has learned his lesson by being sued for insider trading and violating his fiduciary oath in the Bioverativ lawsuit. This is why I always have a skeptical eye towards hedge fund managers, activist shareholders, etc. And with Sarissa controlling the entire board and company that risk is only magnified.

👍️0

rosemountbomber 2 days ago

Liam, I remember well (actually tried to forget) as I was long time invested in Elan as well. Stock had a roller coaster ride a few times. Death spiral. Bapineuzimab was the the AD drug. They also had a situation where their MS drug, Tysabri was found to have caused PML in a few cases. Quite a history.

👍️0

liamlinden 2 days ago

Brave a big negative .I was invested in a stock ELAN Irish company and when a little news was coming out it looked like we hit the jackpot so people mortgaged their houses and results were in Chicago .Every investor/ wall street most of the people from Elan chat room waited and the investigator came on stage and after he spoke 3 words the dirty tabloids had headlines 3DIE from new Elan drug [deaths had nothing to do with the trial they dies falling down stairs and other issues,He then told the room IT FAILED.Small investors lost everything money houses relationships and one guy from elan chat room committed sus .Later it was found out weeks before that I think it was G/SASHS took the investigator out for dinner and paid him $21k so they bought it around $15 and bought up to $36 and before he hit the stage wall street shorted 850 million .Anyway it ended up in court and the investigator got small jail time and G/S just had to pay 350 mil back but was allowed to keep what they invested .Wall Street always wins so lets hope Amrn does not go up as we approach Brave results .I said when holt came in they were going to take this private and I still think they are going to take it private and Denner will make huge money .BO i will take $27

🤡 1

JRoon71 2 days ago

Although Mochida does have an additional indication for arteriosclerosis obliterans in Japan.

👍️0

JRoon71 2 days ago

Great question. But I would assume it was from a generics distributor.

👍️0

TalShu 2 days ago

I don't know. Good question to lawyers who are the only people making money of Amarin nowadays.

👍️0

TalShu 2 days ago

Amarin asserted it has successfully fended off a challenge/threat to its patents in Europe but has never indicateur who posed it.

Could it be from Meiji Seika Pharma Co.?

👍️0

CaptBeer 2 days ago

This I know. However, can they piggy-back the CVD indication off of VAZKEPA, or is China too hard-nosed for that?

👍️0

TalShu 2 days ago

Mochida has never applied for a CVD indication for Epadel anywhere. Neither has it ever pretended Epadel has has such a potential.

👍️0

JRoon71 2 days ago

Ah, got it. I think part of the issue (from what I read in an old article) was that Mochida did not have the money to run additional trials in the U.S. or for additional indications, which is why they seeked out a partnership in the U.S. (with Amarin). They gave the IP to Amarin to develop Vascepa in the U.S., in exchange for milestone payments and future royalties. They partnered with Sumitomo Pharma in China to conduct SHTG trials. Meiji Seika Pharma Co. will be the distributor.

👍️0

CaptBeer 2 days ago

SHTG is not the indication in Japan, yet their Phase III study in China was for SHTG. That's why I asked the question.

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amarin Corp PLC (AMRN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

AMRN News

Form 8-K - Current report

Amarin Board of Directors Announces CEO Transition

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Amarin Reports First Quarter 2024 Business Update and Financial Results

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Amarin Announces Results of Annual General Meeting of Shareholders

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

AMRN Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amarin Corp PLC (AMRN) News

Amarin Corp PLC (AMRN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

AMRN News

Form 8-K - Current report

Amarin Board of Directors Announces CEO Transition

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Amarin Reports First Quarter 2024 Business Update and Financial Results

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Amarin Announces Results of Annual General Meeting of Shareholders

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

AMRN Discussion

Your Recent History

Company

Business

Popular

Get The App